0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Human Rabies Immunoglobulin (IM)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Published Date: August 2025
|
Report Code: QYRE-Auto-39X8702
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Human Rabies Immunoglobulin IM Market Outlook 2022
BUY CHAPTERS

Human Rabies Immunoglobulin (IM)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-39X8702
Report
August 2025
Pages:118
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Rabies Immunoglobulin (IM)- Market Size

The global market for Human Rabies Immunoglobulin (IM) was estimated to be worth US$ 327 million in 2024 and is forecast to a readjusted size of US$ 407 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.

Human Rabies Immunoglobulin (IM)- Market

Human Rabies Immunoglobulin (IM)- Market

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization. In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
The rising incidence of rabies, especially in developing countries, is a key driver of the human rabies immunoglobulin market. Rabies remains a significant public health concern, particularly in regions where animal vaccination programs are insufficient. Post-exposure prophylaxis (PEP), which includes human rabies immunoglobulin, is critical for preventing the virus after a bite from a rabid animal. Increasing awareness of rabies prevention, government initiatives, and partnerships with international health organizations have boosted demand for human rabies immunoglobulin in both rural and urban areas.
A major challenge in the human rabies immunoglobulin market is its limited availability and high cost, particularly in low- and middle-income countries where rabies is most prevalent. The production of immunoglobulins requires advanced technology and biological materials, making it costly and sometimes scarce in regions with insufficient healthcare infrastructure. Additionally, the need for timely administration after exposure poses logistical difficulties, especially in remote areas, where access to healthcare facilities may be delayed, potentially limiting the effectiveness of the treatment.
Asia-Pacific is expected to experience the highest growth in the market during the forecast period.
This report aims to provide a comprehensive presentation of the global market for Human Rabies Immunoglobulin (IM), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Rabies Immunoglobulin (IM) by region & country, by Type, and by Application.
The Human Rabies Immunoglobulin (IM) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Rabies Immunoglobulin (IM).
Market Segmentation

Scope of Human Rabies Immunoglobulin (IM)- Market Report

Report Metric Details
Report Name Human Rabies Immunoglobulin (IM)- Market
Forecasted market size in 2031 US$ 407 million
CAGR 3.2%
Forecasted years 2025 - 2031
Segment by Type
  • ERIG
  • HRIG
Segment by Application
  • Category II Exposure
  • Category III Exposure
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, Tiantan Bio, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Human Rabies Immunoglobulin (IM) in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Human Rabies Immunoglobulin (IM)- Market size in 2031?

Ans: The Human Rabies Immunoglobulin (IM)- Market size in 2031 will be US$ 407 million.

Who are the main players in the Human Rabies Immunoglobulin (IM)- Market report?

Ans: The main players in the Human Rabies Immunoglobulin (IM)- Market are CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, Tiantan Bio, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINS

What are the Application segmentation covered in the Human Rabies Immunoglobulin (IM)- Market report?

Ans: The Applications covered in the Human Rabies Immunoglobulin (IM)- Market report are Category II Exposure, Category III Exposure

What are the Type segmentation covered in the Human Rabies Immunoglobulin (IM)- Market report?

Ans: The Types covered in the Human Rabies Immunoglobulin (IM)- Market report are ERIG, HRIG

1 Market Overview
1.1 Human Rabies Immunoglobulin (IM) Product Introduction
1.2 Global Human Rabies Immunoglobulin (IM) Market Size Forecast
1.2.1 Global Human Rabies Immunoglobulin (IM) Sales Value (2020-2031)
1.2.2 Global Human Rabies Immunoglobulin (IM) Sales Volume (2020-2031)
1.2.3 Global Human Rabies Immunoglobulin (IM) Sales Price (2020-2031)
1.3 Human Rabies Immunoglobulin (IM) Market Trends & Drivers
1.3.1 Human Rabies Immunoglobulin (IM) Industry Trends
1.3.2 Human Rabies Immunoglobulin (IM) Market Drivers & Opportunity
1.3.3 Human Rabies Immunoglobulin (IM) Market Challenges
1.3.4 Human Rabies Immunoglobulin (IM) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Human Rabies Immunoglobulin (IM) Players Revenue Ranking (2024)
2.2 Global Human Rabies Immunoglobulin (IM) Revenue by Company (2020-2025)
2.3 Global Human Rabies Immunoglobulin (IM) Players Sales Volume Ranking (2024)
2.4 Global Human Rabies Immunoglobulin (IM) Sales Volume by Company Players (2020-2025)
2.5 Global Human Rabies Immunoglobulin (IM) Average Price by Company (2020-2025)
2.6 Key Manufacturers Human Rabies Immunoglobulin (IM) Manufacturing Base and Headquarters
2.7 Key Manufacturers Human Rabies Immunoglobulin (IM) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Human Rabies Immunoglobulin (IM)
2.9 Human Rabies Immunoglobulin (IM) Market Competitive Analysis
2.9.1 Human Rabies Immunoglobulin (IM) Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Human Rabies Immunoglobulin (IM) Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Rabies Immunoglobulin (IM) as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 ERIG
3.1.2 HRIG
3.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Type
3.2.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Human Rabies Immunoglobulin (IM) Sales Value, by Type (2020-2031)
3.2.3 Global Human Rabies Immunoglobulin (IM) Sales Value, by Type (%) (2020-2031)
3.3 Global Human Rabies Immunoglobulin (IM) Sales Volume by Type
3.3.1 Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Human Rabies Immunoglobulin (IM) Sales Volume, by Type (2020-2031)
3.3.3 Global Human Rabies Immunoglobulin (IM) Sales Volume, by Type (%) (2020-2031)
3.4 Global Human Rabies Immunoglobulin (IM) Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Category II Exposure
4.1.2 Category III Exposure
4.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Application
4.2.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Human Rabies Immunoglobulin (IM) Sales Value, by Application (2020-2031)
4.2.3 Global Human Rabies Immunoglobulin (IM) Sales Value, by Application (%) (2020-2031)
4.3 Global Human Rabies Immunoglobulin (IM) Sales Volume by Application
4.3.1 Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Human Rabies Immunoglobulin (IM) Sales Volume, by Application (2020-2031)
4.3.3 Global Human Rabies Immunoglobulin (IM) Sales Volume, by Application (%) (2020-2031)
4.4 Global Human Rabies Immunoglobulin (IM) Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Region
5.1.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2020-2025)
5.1.3 Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2026-2031)
5.1.4 Global Human Rabies Immunoglobulin (IM) Sales Value by Region (%), (2020-2031)
5.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Region
5.2.1 Global Human Rabies Immunoglobulin (IM) Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2020-2025)
5.2.3 Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2026-2031)
5.2.4 Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (%), (2020-2031)
5.3 Global Human Rabies Immunoglobulin (IM) Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
5.4.2 North America Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
5.5.2 Europe Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
5.6.2 Asia Pacific Human Rabies Immunoglobulin (IM) Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
5.7.2 South America Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
5.8.2 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value
6.2.1 Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.2.2 Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.3.2 United States Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.4.2 Europe Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.5.2 China Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.5.3 China Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.6.2 Japan Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.7.2 South Korea Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.8.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Human Rabies Immunoglobulin (IM) Sales Value, 2020-2031
6.9.2 India Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
6.9.3 India Human Rabies Immunoglobulin (IM) Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 CSL Behring
7.1.1 CSL Behring Company Information
7.1.2 CSL Behring Introduction and Business Overview
7.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Offerings
7.1.5 CSL Behring Recent Development
7.2 Grifols
7.2.1 Grifols Company Information
7.2.2 Grifols Introduction and Business Overview
7.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Offerings
7.2.5 Grifols Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Information
7.3.2 Sanofi Introduction and Business Overview
7.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Offerings
7.3.5 Sanofi Recent Development
7.4 Sichuan Yuanda Shuyang
7.4.1 Sichuan Yuanda Shuyang Company Information
7.4.2 Sichuan Yuanda Shuyang Introduction and Business Overview
7.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Offerings
7.4.5 Sichuan Yuanda Shuyang Recent Development
7.5 Tiantan Bio
7.5.1 Tiantan Bio Company Information
7.5.2 Tiantan Bio Introduction and Business Overview
7.5.3 Tiantan Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Tiantan Bio Human Rabies Immunoglobulin (IM) Product Offerings
7.5.5 Tiantan Bio Recent Development
7.6 Kamada
7.6.1 Kamada Company Information
7.6.2 Kamada Introduction and Business Overview
7.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Offerings
7.6.5 Kamada Recent Development
7.7 CBPO
7.7.1 CBPO Company Information
7.7.2 CBPO Introduction and Business Overview
7.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Offerings
7.7.5 CBPO Recent Development
7.8 Shuanglin Bio
7.8.1 Shuanglin Bio Company Information
7.8.2 Shuanglin Bio Introduction and Business Overview
7.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Offerings
7.8.5 Shuanglin Bio Recent Development
7.9 Weiguang Bio
7.9.1 Weiguang Bio Company Information
7.9.2 Weiguang Bio Introduction and Business Overview
7.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Offerings
7.9.5 Weiguang Bio Recent Development
7.10 Shanghai RAAS
7.10.1 Shanghai RAAS Company Information
7.10.2 Shanghai RAAS Introduction and Business Overview
7.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Offerings
7.10.5 Shanghai RAAS Recent Development
7.11 Bharat Serum
7.11.1 Bharat Serum Company Information
7.11.2 Bharat Serum Introduction and Business Overview
7.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Offerings
7.11.5 Bharat Serum Recent Development
7.12 VINS
7.12.1 VINS Company Information
7.12.2 VINS Introduction and Business Overview
7.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 VINS Human Rabies Immunoglobulin (IM) Product Offerings
7.12.5 VINS Recent Development
8 Industry Chain Analysis
8.1 Human Rabies Immunoglobulin (IM) Industrial Chain
8.2 Human Rabies Immunoglobulin (IM) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Human Rabies Immunoglobulin (IM) Sales Model
8.5.2 Sales Channel
8.5.3 Human Rabies Immunoglobulin (IM) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
 Table 1. Human Rabies Immunoglobulin (IM) Market Trends
 Table 2. Human Rabies Immunoglobulin (IM) Market Drivers & Opportunity
 Table 3. Human Rabies Immunoglobulin (IM) Market Challenges
 Table 4. Human Rabies Immunoglobulin (IM) Market Restraints
 Table 5. Global Human Rabies Immunoglobulin (IM) Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Human Rabies Immunoglobulin (IM) Revenue Market Share by Company (2020-2025)
 Table 7. Global Human Rabies Immunoglobulin (IM) Sales Volume by Company (2020-2025) & (K Units)
 Table 8. Global Human Rabies Immunoglobulin (IM) Sales Volume Market Share by Company (2020-2025)
 Table 9. Global Market Human Rabies Immunoglobulin (IM) Price by Company (2020-2025) & (US$/Unit)
 Table 10. Key Manufacturers Human Rabies Immunoglobulin (IM) Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Human Rabies Immunoglobulin (IM) Product Type
 Table 12. Key Manufacturers Time to Begin Mass Production of Human Rabies Immunoglobulin (IM)
 Table 13. Global Human Rabies Immunoglobulin (IM) Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Rabies Immunoglobulin (IM) as of 2024)
 Table 15. Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Rabies Immunoglobulin (IM) Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 17. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2020-2025) & (US$ Million)
 Table 18. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2026-2031) & (US$ Million)
 Table 19. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Value by Type (2020-2025)
 Table 20. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Value by Type (2026-2031)
 Table 21. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
 Table 22. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2020-2025) & (K Units)
 Table 23. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2026-2031) & (K Units)
 Table 24. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Volume by Type (2020-2025)
 Table 25. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Volume by Type (2026-2031)
 Table 26. Global Human Rabies Immunoglobulin (IM) Price by Type (2020-2025) & (US$/Unit)
 Table 27. Global Human Rabies Immunoglobulin (IM) Price by Type (2026-2031) & (US$/Unit)
 Table 28. Global Human Rabies Immunoglobulin (IM) Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 29. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2020-2025) & (US$ Million)
 Table 30. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2026-2031) & (US$ Million)
 Table 31. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Value by Application (2020-2025)
 Table 32. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Value by Application (2026-2031)
 Table 33. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
 Table 34. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2020-2025) & (K Units)
 Table 35. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2026-2031) & (K Units)
 Table 36. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Volume by Application (2020-2025)
 Table 37. Global Human Rabies Immunoglobulin (IM) Sales Market Share in Volume by Application (2026-2031)
 Table 38. Global Human Rabies Immunoglobulin (IM) Price by Application (2020-2025) & (US$/Unit)
 Table 39. Global Human Rabies Immunoglobulin (IM) Price by Application (2026-2031) & (US$/Unit)
 Table 40. Global Human Rabies Immunoglobulin (IM) Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 41. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2020-2025) & (US$ Million)
 Table 42. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2026-2031) & (US$ Million)
 Table 43. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2020-2025) & (%)
 Table 44. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2026-2031) & (%)
 Table 45. Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
 Table 46. Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2020-2025) & (K Units)
 Table 47. Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2026-2031) & (K Units)
 Table 48. Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2020-2025) & (%)
 Table 49. Global Human Rabies Immunoglobulin (IM) Sales Volume by Region (2026-2031) & (%)
 Table 50. Global Human Rabies Immunoglobulin (IM) Average Price by Region (2020-2025) & (US$/Unit)
 Table 51. Global Human Rabies Immunoglobulin (IM) Average Price by Region (2026-2031) & (US$/Unit)
 Table 52. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 53. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value, (2020-2025) & (US$ Million)
 Table 54. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value, (2026-2031) & (US$ Million)
 Table 55. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Volume, (2020-2025) & (K Units)
 Table 56. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Volume, (2026-2031) & (K Units)
 Table 57. CSL Behring Company Information
 Table 58. CSL Behring Introduction and Business Overview
 Table 59. CSL Behring Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 60. CSL Behring Human Rabies Immunoglobulin (IM) Product Offerings
 Table 61. CSL Behring Recent Development
 Table 62. Grifols Company Information
 Table 63. Grifols Introduction and Business Overview
 Table 64. Grifols Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 65. Grifols Human Rabies Immunoglobulin (IM) Product Offerings
 Table 66. Grifols Recent Development
 Table 67. Sanofi Company Information
 Table 68. Sanofi Introduction and Business Overview
 Table 69. Sanofi Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 70. Sanofi Human Rabies Immunoglobulin (IM) Product Offerings
 Table 71. Sanofi Recent Development
 Table 72. Sichuan Yuanda Shuyang Company Information
 Table 73. Sichuan Yuanda Shuyang Introduction and Business Overview
 Table 74. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 75. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Offerings
 Table 76. Sichuan Yuanda Shuyang Recent Development
 Table 77. Tiantan Bio Company Information
 Table 78. Tiantan Bio Introduction and Business Overview
 Table 79. Tiantan Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 80. Tiantan Bio Human Rabies Immunoglobulin (IM) Product Offerings
 Table 81. Tiantan Bio Recent Development
 Table 82. Kamada Company Information
 Table 83. Kamada Introduction and Business Overview
 Table 84. Kamada Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 85. Kamada Human Rabies Immunoglobulin (IM) Product Offerings
 Table 86. Kamada Recent Development
 Table 87. CBPO Company Information
 Table 88. CBPO Introduction and Business Overview
 Table 89. CBPO Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. CBPO Human Rabies Immunoglobulin (IM) Product Offerings
 Table 91. CBPO Recent Development
 Table 92. Shuanglin Bio Company Information
 Table 93. Shuanglin Bio Introduction and Business Overview
 Table 94. Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 95. Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Offerings
 Table 96. Shuanglin Bio Recent Development
 Table 97. Weiguang Bio Company Information
 Table 98. Weiguang Bio Introduction and Business Overview
 Table 99. Weiguang Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 100. Weiguang Bio Human Rabies Immunoglobulin (IM) Product Offerings
 Table 101. Weiguang Bio Recent Development
 Table 102. Shanghai RAAS Company Information
 Table 103. Shanghai RAAS Introduction and Business Overview
 Table 104. Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 105. Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Offerings
 Table 106. Shanghai RAAS Recent Development
 Table 107. Bharat Serum Company Information
 Table 108. Bharat Serum Introduction and Business Overview
 Table 109. Bharat Serum Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 110. Bharat Serum Human Rabies Immunoglobulin (IM) Product Offerings
 Table 111. Bharat Serum Recent Development
 Table 112. VINS Company Information
 Table 113. VINS Introduction and Business Overview
 Table 114. VINS Human Rabies Immunoglobulin (IM) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 115. VINS Human Rabies Immunoglobulin (IM) Product Offerings
 Table 116. VINS Recent Development
 Table 117. Key Raw Materials Lists
 Table 118. Raw Materials Key Suppliers Lists
 Table 119. Human Rabies Immunoglobulin (IM) Downstream Customers
 Table 120. Human Rabies Immunoglobulin (IM) Distributors List
 Table 121. Research Programs/Design for This Report
 Table 122. Key Data Information from Secondary Sources
 Table 123. Key Data Information from Primary Sources


List of Figures
 Figure 1. Human Rabies Immunoglobulin (IM) Product Picture
 Figure 2. Global Human Rabies Immunoglobulin (IM) Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Human Rabies Immunoglobulin (IM) Sales Value (2020-2031) & (US$ Million)
 Figure 4. Global Human Rabies Immunoglobulin (IM) Sales Volume (2020-2031) & (K Units)
 Figure 5. Global Human Rabies Immunoglobulin (IM) Sales Price (2020-2031) & (US$/Unit)
 Figure 6. Human Rabies Immunoglobulin (IM) Report Years Considered
 Figure 7. Global Human Rabies Immunoglobulin (IM) Players Revenue Ranking (2024) & (US$ Million)
 Figure 8. Global Human Rabies Immunoglobulin (IM) Players Sales Volume Ranking (2024) & (K Units)
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Human Rabies Immunoglobulin (IM) Revenue in 2024
 Figure 10. Human Rabies Immunoglobulin (IM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 11. ERIG Picture
 Figure 12. HRIG Picture
 Figure 13. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 14. Global Human Rabies Immunoglobulin (IM) Sales Value Market Share by Type, 2024 & 2031
 Figure 15. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
 Figure 16. Global Human Rabies Immunoglobulin (IM) Sales Volume Market Share by Type, 2024 & 2031
 Figure 17. Global Human Rabies Immunoglobulin (IM) Price by Type (2020-2031) & (US$/Unit)
 Figure 18. Product Picture of Category II Exposure
 Figure 19. Product Picture of Category III Exposure
 Figure 20. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 21. Global Human Rabies Immunoglobulin (IM) Sales Value Market Share by Application, 2024 & 2031
 Figure 22. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
 Figure 23. Global Human Rabies Immunoglobulin (IM) Sales Volume Market Share by Application, 2024 & 2031
 Figure 24. Global Human Rabies Immunoglobulin (IM) Price by Application (2020-2031) & (US$/Unit)
 Figure 25. North America Human Rabies Immunoglobulin (IM) Sales Value (2020-2031) & (US$ Million)
 Figure 26. North America Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
 Figure 27. Europe Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 28. Europe Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
 Figure 29. Asia Pacific Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 30. Asia Pacific Human Rabies Immunoglobulin (IM) Sales Value by Region (%), 2024 VS 2031
 Figure 31. South America Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 32. South America Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
 Figure 33. Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 34. Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value by Country (%), 2024 VS 2031
 Figure 35. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Value (%), (2020-2031)
 Figure 36. Key Countries/Regions Human Rabies Immunoglobulin (IM) Sales Volume (%), (2020-2031)
 Figure 37. United States Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 38. United States Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 39. United States Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 40. Europe Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 41. Europe Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 42. Europe Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 43. China Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 44. China Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 45. China Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 46. Japan Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 47. Japan Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 48. Japan Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 49. South Korea Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 50. South Korea Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 51. South Korea Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 52. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 53. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 54. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 55. India Human Rabies Immunoglobulin (IM) Sales Value, (2020-2031) & (US$ Million)
 Figure 56. India Human Rabies Immunoglobulin (IM) Sales Value by Type (%), 2024 VS 2031
 Figure 57. India Human Rabies Immunoglobulin (IM) Sales Value by Application (%), 2024 VS 2031
 Figure 58. Human Rabies Immunoglobulin (IM) Industrial Chain
 Figure 59. Human Rabies Immunoglobulin (IM) Manufacturing Cost Structure
 Figure 60. Channels of Distribution (Direct Sales, and Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

RELATED REPORTS

Global Hepatitis B Virus Core Antibody Diagnostic Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21N6899
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Pediatric Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13M6952
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Poliomyelitis Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29X7355
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Varicella Virus (Chickenpox) Vaccine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28B293
Tue Sep 09 00:00:00 UTC 2025

Add to Cart